Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Stock-based Compensation

v3.22.2.2
Note 12 - Stock-based Compensation
3 Months Ended
Jul. 03, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

Note 12 Stock-based Compensation

 

The Company has three incentive stock plans, the 2006 Omnibus Incentive Plan (the “2006 Plan”), the 2014 Omnibus Equity Compensation Plan (the “2014 Plan”) and the 2021 Incentive Plan (the “2021 Plan”). As a result of the approval of the 2014 Plan by the Company’s stockholders at the Company’s 2014 annual meeting and the 2021 Plan by the Company’s stockholders at the Company’s 2021 annual meeting, grants may no longer be issued under either the 2006 Plan or the 2014 Plan. As of July 3, 2022, 852,335 shares of the Company’s common stock were available for future issuance under the 2021 Plan, which may be issued from authorized and unissued shares of the Company’s common stock or treasury shares. The Company recorded stock-based compensation expense of $333,000 and $132,000 during the three months ended July 3, 2022 and June 27, 2021, respectively. The Company records the compensation expense associated with stock-based awards granted to individuals in the same expense classifications as the cash compensation paid to those same individuals. No stock-based compensation costs were capitalized as part of the cost of an asset as of July 3, 2022.

 

Stock Options: The following table represents stock option activity for the three-month periods ended July 3, 2022 and June 27, 2021:

 

   

Three-Month Periods Ended

 
   

July 3, 2022

   

June 27, 2021

 
   

Weighted-

           

Weighted-

         
   

Average

   

Number of

   

Average

   

Number of

 
   

Exercise

   

Options

   

Exercise

   

Options

 
   

Price

   

Outstanding

   

Price

   

Outstanding

 

Outstanding at Beginning of Period

  $ 7.39       635,500     $ 6.84       567,500  

Granted

    6.54       120,000       7.98       158,000  

Exercised

    4.92       (15,000 )     4.84       (30,000 )

Outstanding at End of Period

    7.31       740,500       7.18       695,500  

Exercisable at End of Period

    7.40       504,000       7.19       407,500  

 

As of July 3, 2022, the intrinsic value of the outstanding and exercisable stock options was $152,000. The intrinsic value of the stock options exercised during the three-month period ended July 3, 2022 was $20,000.

 

Upon the exercise of stock options, participants may choose to surrender to the Company those shares from the option exercise necessary to satisfy the exercise amount and their income tax withholding obligations that arise from the option exercise. The effect on the cash flow of the Company from these “cashless” option exercises is that the Company remits cash on behalf of the participant to satisfy his or her income tax withholding obligations. The Company used cash to remit the required income tax withholding amounts from “cashless” option exercises of $8,000 and $34,000 during the three months ended July 3, 2022 and June 27, 2021, respectively.

 

Stock-based compensation is calculated according to FASB ASC Topic 718, Compensation Stock Compensation, which requires stock-based compensation to be accounted for using a fair-value-based measurement. To determine the estimated fair value of stock options granted, the Company uses the Black-Scholes-Merton valuation formula, which is a closed-form model that uses an equation to estimate fair value. The following table sets forth the assumptions used to determine the fair value of the non-qualified stock options that were awarded to certain employees during the three-month periods ended July 3, 2022 and June 27, 2021, which options vest over a two-year period, assuming continued service.

 

   

Three-Month Periods Ended

 
   

July 3, 2022

   

June 27, 2021

 

Number of options issued

    120,000       158,000  

Grant date

 

June 7, 2022

   

June 9, 2021

 

Dividend yield

    4.89 %     4.00 %

Expected volatility

    30.00 %     35.00 %

Risk free interest rate

    2.95 %     0.53 %

Contractual term (years)

    10.00       10.00  

Expected term (years)

    4.00       4.00  

Forfeiture rate

    5.00 %     5.00 %

Exercise price (grant-date closing price) per option

  $ 6.54     $ 7.98  

Fair value per option

  $ 0.90     $ 1.61  

 

During the three-month periods ended July 3, 2022 and June 27, 2021, the Company classified its compensation expense associated with stock options within the accompanying unaudited condensed consolidated statements of income as follows (in thousands):

 

   

Three-Month Period Ended July 3, 2022

   

Three-Month Period Ended June 27, 2021

 
   

Cost of

   

Marketing &

           

Cost of

   

Marketing &

         
   

Products

   

Administrative

   

Total

   

Products

   

Administrative

   

Total

 

Options Granted in Fiscal Year

 

Sold

   

Expenses

   

Expense

   

Sold

   

Expenses

   

Expense

 

2020

  $ -     $ -     $ -     $ 3     $ 4     $ 7  

2021

    3       11       14       4       16       20  

2022

    12       30       42       2       4       6  

2023

    2       2       4       -       -       -  
                                                 

Total stock option compensation

  $ 17     $ 43     $ 60     $ 9     $ 24     $ 33  

 

As of July 3, 2022, total unrecognized stock option compensation expense amounted to $249,000, which will be recognized as the underlying stock options vest over a weighted-average period of 13.4 months. The amount of future stock option compensation expense could be affected by any future stock option grants and by the separation from the Company of any individual who has received stock options that are unvested as of such individual’s separation date.

 

Non-vested Stock Granted to Directors: The following shares of non-vested stock were granted to the Company’s directors:

 

Number of Shares

   

Fair Value per Share

 

Grant Date

 

Vesting Period (Years)

40,165     $7.47  

August 11, 2021

 

One

41,452     5.79  

August 12, 2020

 

Two

46,512     5.16  

August 14, 2019

 

Two

 

The fair value of the non-vested stock granted to the Company’s directors was based on the closing price of the Company’s common stock on the date of each grant. The non-vested stock granted on August 11, 2021 included 8,033 shares granted to E. Randall Chestnut, formerly the Company’s Chairman, President and Chief Executive Officer. On May 1, 2022, upon the resignation of Mr. Chestnut from the Board and his retirement from all positions that he held within the Company, the vesting of these 8,033 shares was accelerated, with such shares having an aggregate value on such date of $50,000. The remaining shares set forth above otherwise vest over the periods indicated, assuming continued service.

 

Non-vested Stock Granted to Employees: The following shares of non-vested stock were granted to certain of the Company’s employees:

 

Number of Shares

   

Fair Value per Share

 

Grant Date

 

Vesting Date

20,000     $4.92  

June 10, 2020

 

June 10, 2022

10,000     7.60  

February 22, 2021

 

February 22, 2023

25,000     7.98  

June 9, 2021

 

June 9, 2022

 

These shares vest on the dates indicated, assuming continued service. In June 2022, 45,000 shares that had been granted to certain of the Company’s employees vested, having an aggregate value on their respective vesting dates of $293,000.

 

Performance Award Shares: On  March 1, 2022, performance awards were granted to certain of the Company’s executive officers, consisting of 187,500 shares, of which: (a) 75,000 shares shall be earned if the closing price per share of the Company’s stock equals or exceeds $8.00 on ten trading days within any period of twenty consecutive trading days prior to  March 1, 2027; and (b) 112,500 shares shall be earned if the closing price per share of the Company’s stock equals or exceeds $9.00 on ten trading days within any period of twenty consecutive trading days prior to  March 1, 2027.  Upon the achievement of each applicable stock hurdle described above: (i) one-third of the shares that are earned shall vest on the later of the date on which the shares are earned and  March 1, 2023; (ii) one-third of the shares that are earned shall vest on the first anniversary of the date on which the shares are earned; (iii) one-third shall vest on the second anniversary of the date on which the shares are earned. All shares that are non-earned or non-vested will be forfeited upon the termination of service. The Company, with the assistance of an independent third party, determined that the grant date fair value of the awards amounted to $732,000.

 

During the three-month periods ended July 3, 2022 and June 27, 2021, the Company recorded compensation expense associated with stock grants, which is included in marketing and administrative expenses in the accompanying unaudited condensed consolidated statements of income, as follows (in thousands):

 

   

Three-Month Period Ended July 3, 2022

   

Three-Month Period Ended June 27, 2021

 
           

Non-employee

   

Total

           

Non-employee

   

Total

 

Stock Granted in Fiscal Year

 

Employees

   

Directors

   

Expense

   

Employees

   

Directors

   

Expense

 

2020

  $ -     $ -     $ -     $ -     $ 30     $ 30  

2021

    18       30       48       22       30       52  

2022

    145       80       225       17       -       17  
                                                 

Total stock grant compensation

  $ 163     $ 110     $ 273     $ 39     $ 60     $ 99  

 

As of July 3, 2022, total unrecognized compensation expense related to the Company’s non-vested stock grants amounted to $636,000, which will be recognized over the respective vesting terms associated with each block of non-vested stock indicated above, such grants having an aggregate weighted-average vesting term of 15.0 months. The amount of future compensation expense related to the Company’s non-vested stock grants could be affected by any future non-vested stock grants and by the separation from the Company of any individual who has non-vested stock grants as of such individual’s separation date.